OTTAWA, ON – Tuesday, May 29th, 2018 BioCanRx and its partners are pleased to announce $22,564,174 in funding towards eight new projects: two clinical trials, two Enabling Study projects, three Catalyst projects, and one Clinical, Social & Economic Impact project. These projects come out of the latest round of BioCanRx’s full applications. … Read more »
Category: News
Smoothing the road to the clinic
By Heather Blumenthal The scientific hurdles involved in taking an idea from the laboratory to the clinic are enormous. But in the case of immunotherapies, the hurdles aren’t just scientific – they’re legal, they’re economic and they’re health-system related, areas that aren’t necessarily covered in a scientific education. That’s why Tania Bubela’s contribution is… Read more »
Introducing the winners of BioCanRx’s 2018 Summer Studentships
BioCanRx is pleased to introduce you to the 15 undergraduate students chosen from across Canada through a competitive application process to be part of our Summer Studentship Program. The program’s goal is to inspire the next generation of highly qualified personnel to pursue research in cancer immuno-oncology. Undergraduate and college students receive funding to conduct… Read more »
BioCanRx Lab Exchange at the Biotherapeutics Manufacturing Centre in Ottawa
By Dr. Piriya Yoganathan & Dr. Eric Yung High response rates in refractory B-cell leukemias and lymphomas have been achieved recently using chimeric antigen receptor (CAR) T cell therapy by targeting the CD19 B-lymphocyte antigen. CAR-T cell therapy is a highly personalized treatment that requires the incorporation of a synthetic CAR gene to a… Read more »
Improving Anal Cancer Research through the CORMAC Study
BioCanRx HQP member Allison McNamara spoke with Helene Hutchings, member of the Cancer Stakeholder Alliance Working Group, about her participation in the study Much progress of cancer research has come directly from the multitude of scientists in the laboratory setting, however a new paradigm that involves not only scientists but the collaboration of cancer… Read more »
Breaking new ground in immunotherapy to treat cancer
By Heather Blumenthal Senior Scientist, Cancer Therapeutics Program at the Ottawa Hospital Research Institute. Professor, Departments of Medicine and Biochemistry, Microbiology & Immunology, University of Ottawa. Co- Director, The ACTION Translational Research Initiative at the Ontario Institute for Cancer Research. Director, Canadian Oncolytic Virus Consortium, Terry Fox New Frontiers Program Project Grant. And,… Read more »
Coming at cancer immunotherapy through macrophages
By: Heather Blumenthal It started about five years ago, with a simple question: if T-cells can be activated to fight cancer, “why only do T-cells? What other ways are there of advancing immune responses in cancer?” The question was asked by the University of Toronto’s Dr. Sachdev Sidhu and his collaborators, and it… Read more »
World Cancer Day 2018
A message from Dr. John Bell, Scientific Director and Stéphanie Michaud, President & CEO Cancer is a disease that knows no boundaries. It is a leading cause of death worldwide, responsible for 8.8 million deaths per year. The disease is one of the biggest health challenges facing Canadians: 2 in every 5 of us… Read more »
BioCanRx and Partners New Project Funding Announcement
OTTAWA, ON – Friday, February 2, 2018 – BioCanRx and its partners today announce $1,917,833 in funding for two collaborative research projects and the second-stage funding of a current Catalyst project led by Dr. Simon Turcotte. These projects come out of the latest round of BioCanRx’s full applications. Funding partners for these projects include Formation… Read more »
A Look Back at the First Year of the Cancer Stakeholder Alliance
By: Patrick Sullivan, Chair of the BioCanRx Cancer Stakeholder Alliance Working Group I have been asked to give an update on the Cancer Stakeholder Alliance (CSA) created by BioCanRx. BioCanRx created the CSA because they (rightly) recognized that patients have an important and powerful voice that is critically important to advancing cancer immunotherapies. 2017… Read more »
